Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,689.48๏ฟฅ. Average daily volumn in 3 months 2.28M. Market cap 5.87T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,570.00๏ฟฅ. Total volume : 2.39M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,570.00๏ฟฅ
Change
97.00
Volume
2.39M

Previous Close3,473.00
Open3,526.00
Day Range3,515.00-3,585.00
Bid3,570.00 x N/A
Ask3,571.00 x N/A
Volume2.39M
Average Volume2.28M
Market Cap5.87T
Beta0.66
52 Week Range3,258.00-4,640.00
Trailing P/E15.16
Foward P/E18.73
Dividend (Yield %)2.30%
Ex-Dividend Date2022-06-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept... , and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Market Cap:
5.87T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B



News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Source from : ใƒ‹ใƒƒใ‚ฑใ‚คใƒปใ‚จใ‚คใ‚ธใ‚ข - 19 days ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»


Chugai Pharmaceutical Co Ltd - Stock Valuation CHGCF

Source from : Morningstar%2c Inc. - 10 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Chugai Pharmaceutical Co Ltd - Stock Ownership CUP

Source from : Morningstar%2c Inc. - 8 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...See details»


Chugai introduces Vabysmo intravitreal injection to treat AMD associated with subfoveal choroidal neovascularization and DME

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd. announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 mg/mL [generic name: faricimab (genetical recombination)] for the ...See details»


Japan to purchase antibody cocktail for Covid-19 treatment

Source from : Hindustan Times - 1 year ago

Chugai Pharmaceutical concluded the agreement with Roche in December for the production and marketing in Japan of the antibody cocktail for the virus treatment. A cocktail of two virus ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,...

Source from : Benzinga.com - 10 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


Spinal Muscular Atrophy Market To Surpass US$ 4,346.33 Million By 2030 - Coherent Market Insights'

Source from : Middle East North Africa Financial Network - 10 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


rare diseases

Source from : PMLiVE - 1 month ago

AstraZenecaโ€™s (AZ) rare disease group subsiduary Alexion has reached a settlement agreement with Chugai Pharmaceutical Co (Chugai). ... of people affected by rare diseases.โ€. As an international, ...See details»


galderma-announces-positive-data-from-phase-iii-trial-demonstrating-efficacy-and-safety-of-nemolizumab-in-patients-with-prurigo-nodularis-image

Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis

Source from : Joplin Globe - 3 days ago

Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared ...See details»


Human Herpesvirus 6-Associated Hemophagocytic Syndrome in a Healthy Adult

Source from : Medscape - 1 month ago

On day 14 after admission, at the onset of pancytopenia, subcutaneous administration of recombinant human G-CSF (Lenograstim; Chugai Pharmaceutical Co. LTD., Tokyo, Japan) was started at 2 ยตg/kg.See details»


Autoimmune Treatment Market Size, Business Revenue Forecast, Leading Competitors and Growth Trends

Source from : Digital Journal - 1 month ago

Autoimmune disease is a medical condition that causes abnormalities in the immune response and triggers damage to the healthy body tissues. The increasing prevalence of autoimmune diseases all ...See details»


Joint pain injection Market New Report Examines By Top Companies Anika Therapeutics, OrthogenRx, Flexion Therapeutics

Source from : Digital Journal - 1 month ago

According to the insight partners new research study on โ€œJoint Pain Injection Market Forecast to 2027 โ€“ COVID-19 Impact and Global Analysis โ€“ by Drug, Joint Type, and Distribution Channel ...See details»


Mitsubishi Electric Announces Director Candidates

Source from : Yahoo Finance - 1 month ago

TOKYO, May 25, 2022--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO Prime Market: 6503) announces that it has received the interim report on the results of the company-wide investigation ...See details»


Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

Source from : ascopubs.org - 1 month ago

Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) ...See details»